- Trials with a EudraCT protocol (18)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
18 result(s) found for: Anaplastic oligodendroglioma.
Displaying page 1 of 1.
| EudraCT Number: 2009-017422-39 | Sponsor Protocol Number: 26091 | Start Date*: 2010-12-23 | |||||||||||||||||||||
| Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||||||||||||
| Full Title: Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial. | |||||||||||||||||||||||
| Medical condition: Recurrent grade II and grade III gliomas | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: NL (Completed) DE (Completed) BE (Completed) GB (Completed) IT (Completed) AT (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2008-007295-14 | Sponsor Protocol Number: 26081-22086 | Start Date*: 2010-11-17 | ||||||||||||||||||||||||||
| Sponsor Name:European Organization for Research and Treatment of Cancer (EORTC) | ||||||||||||||||||||||||||||
| Full Title: Phase III intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with concomitant and adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma. | ||||||||||||||||||||||||||||
| Medical condition: Newly Diagnosed Anaplastic Glioma with Chromosomal co-deletions of 1p and 19q | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: NL (Prematurely Ended) BE (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2010-022189-28 | Sponsor Protocol Number: BO25041 | Start Date*: 2011-08-12 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: A PHASE II OPEN-LABEL, RANDOMIZED, MULTI- CENTRE COMPARATIVE STUDY OF BEVACIZUMAB-BASED THERAPY IN PAEDIATRIC PATIENTS WITH NEWLY DIAGNOSED SUPRATENTORIAL, INFRATENTORIAL CEREBELLAR, OR PEDUNCULAR ... | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Newly diagnosed high-grade glioma | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Completed) AT (Completed) CZ (Completed) DE (Completed) GB (Completed) SE (Completed) HU (Completed) FR (Completed) ES (Completed) DK (Completed) FI (Prematurely Ended) NL (Completed) IT (Completed) PL (Completed) Outside EU/EEA | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2009-011898-33 | Sponsor Protocol Number: HIT-HGG-CilMetro | Start Date*: 2011-11-28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Martin-Luther-Universität Halle-Wittenberg | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Treatment of relapsed or refractory high grade gliomas and diffuse intrinsic pontine gliomas in paediatric patients ≥ 3 years and < 18 years of age. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2007-000128-42 | Sponsor Protocol Number: HIT-HGG-2007 | Start Date*: 2009-03-19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Martin-Luther-University Halle-Wittenberg | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: International cooperative Phase II trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children ≥ 3 years and adole... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: 1st line therapy of newly diagnosed, previously untreated high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents ≥ 3 years and < 18 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) AT (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2013-003668-30 | Sponsor Protocol Number: KCP-330-004 | Start Date*: 2013-11-12 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Karyopharm Therapeutic, Inc. | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients with Recurrent Gliomas | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Recurrent glioblastoma or other brain cancer after failure of radiation therapy and temozolomide | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: DK (Prematurely Ended) NL (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2006-001545-34 | Sponsor Protocol Number: TCLGG | Start Date*: 2006-03-22 | |||||||||||
| Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI | |||||||||||||
| Full Title: Evaluating primary chemotherapy with temozolomide continuative low dose in patients with low grade gliomas grade II WHO | |||||||||||||
| Medical condition: First line chemotherapy in low grade glioma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-005027-16 | Sponsor Protocol Number: NOA-18 | Start Date*: 2020-09-16 | ||||||||||||||||
| Sponsor Name:Heidelberg University Hospital Represented in law by its Commercial Managing Director | ||||||||||||||||||
| Full Title: Improvement of functional Outcome for patients with newly diagnosed grade 2 or 3 glioma with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial | ||||||||||||||||||
| Medical condition: WHO grade 2 or 3 glioma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2006-001533-17 | Sponsor Protocol Number: EORTC26053-22054 | Start Date*: 2007-06-25 | |||||||||||
| Sponsor Name:EORTC European Organisation for research and treatment of cancer | |||||||||||||
| Full Title: Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial. | |||||||||||||
| Medical condition: anaplastic glioma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) DE (Completed) FR (Completed) IT (Completed) BE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-001278-26 | Sponsor Protocol Number: VEG102857 | Start Date*: 2006-10-31 |
| Sponsor Name:GlaxoSmithKline Research & Development Limited | ||
| Full Title: Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma | ||
| Medical condition: Relaped Malignant Glioma = patients with anaplastic astrocytoma, anaplastic oligodendroglioma, mixed anaplastic oligoastrocytoma, glioblastoma multiforme or gliosarcoma at recurrence | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-018447-34 | Sponsor Protocol Number: 06MH34 | Start Date*: 2011-09-22 | |||||||||||
| Sponsor Name:Great Ormond Street Hospital for Children NHS Trust | |||||||||||||
| Full Title: Investigation of dendritic cell vaccine immunotherapy in paediatric high grade glioma | |||||||||||||
| Medical condition: Paediatric High grade glioma, excluding brain stem gliomas | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-005573-21 | Sponsor Protocol Number: GLIOMARK1 | Start Date*: 2016-04-26 | |||||||||||
| Sponsor Name:pro-ACTINA S.A. | |||||||||||||
| Full Title: Exploratory phase II study in patients after treatment of high grade brain tumors to assess the technical performance of Tc-99m tetrofosmin for differentiation of recurrence versus radiation necrosis | |||||||||||||
| Medical condition: Patients with high grade brain tumors | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) FR (Completed) HU (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-005219-16 | Sponsor Protocol Number: GE-135-003 | Start Date*: 2010-12-06 |
| Sponsor Name:GE Healthcare Ltd | ||
| Full Title: A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis via the Expression of avb3 Integrin Receptors by [18F]AH111585 PET Imaging | ||
| Medical condition: Adult subjects with Primary or metastatic tumour lesion of one of the following types: high-grade glioma, including GBM, anaplastic astrocytoma, and anaplastic oligodendroglioma; lung cancer, inclu... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2018-004459-19 | Sponsor Protocol Number: CDRB436G2401 | Start Date*: 2019-07-31 |
| Sponsor Name:Novartis Farmacéutica S.A. | ||
| Full Title: An open label, multi-center roll-over study to assess long-term effect in pediatric patients treated with Tafinlar (dabrafenib) and/or Mekinist (trametinib) | ||
| Medical condition: Children and Adolescents with Cancers Harboring V600 mutations | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) SE (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2011-004671-37 | Sponsor Protocol Number: GEINO-11 | Start Date*: 2011-12-19 |
| Sponsor Name:GRUPO ESPAÑOL DE INVESTIGACION EN NEUROONCOLOGIA | ||
| Full Title: Phase II pilot, prospective, open label, multicenter Clinical Trial, to evaluate the safety and efficacy of PF299804, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with ... | ||
| Medical condition: Patients with recurrent glioblastoma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-005617-14 | Sponsor Protocol Number: CLEE011Q12101 | Start Date*: 2022-10-10 |
| Sponsor Name:Novartis Farmacéutica, S.A. | ||
| Full Title: Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory neuroblast... | ||
| Medical condition: relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma) in patients from 12 months to 21 years old | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-000627-20 | Sponsor Protocol Number: F8394-201 | Start Date*: 2023-02-07 | ||||||||||||||||
| Sponsor Name:Fore Biotherapeutics | ||||||||||||||||||
| Full Title: A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations | ||||||||||||||||||
| Medical condition: Tumors harboring BRAF alterations | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) DE (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2006-003193-10 | Sponsor Protocol Number: CDKO-125a-002 | Start Date*: 2009-02-24 | ||||||||||||||||
| Sponsor Name:Nerviano Medical Sciences S.r.l. | ||||||||||||||||||
| Full Title: A phase I/II study of oral PHA-848125AC given daily for 14 consecutive days every 3 weeks in recurrent malignant glioma | ||||||||||||||||||
| Medical condition: Phase I Part: Recurrent Malignant Glioma Phase II Part: Recurrent Glioblastoma Multiforme | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Completed) ES (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
